DataM Intelligence | competitive Intelligence Emerging TED therapies aim to outpace Tepezza with safer, more convenient, and longer-lasting ...

Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

Discover key insights from Roivant Sciences' Q4 2024 earnings call. Learn about their robust pipeline, pivotal 2025 milestones, and capital strength.